Back to top
more

iRadimed (IRMD)

(Real Time Quote from BATS)

$70.36 USD

70.36
19,071

+0.79 (1.14%)

Updated Aug 6, 2025 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

by Zacks Equity Research

iRadimed (IRMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Acadia Healthcare (ACHC) Up 11% in 3 Months: More Room to Run?

by Zacks Equity Research

Acadia Healthcare (ACHC) is well-poised for growth on an expansive healthcare portfolio, which in turn, boosts its patient volumes.

Zacks Equity Research

Zacks.com featured highlights Perdoceo Education, Boot Barn and iRadimed

by Zacks Equity Research

Perdoceo Education, Boot Barn and iRadimed have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Top Profitable Stocks to Invest in Using Net Income Ratio

by Tirthankar Chakraborty

Perdoceo Education (PRDO), Boot Barn (BOOT) and iRadimed (IRMD) have been selected as the top picks with a high net income ratio.

Ethan Feller headshot

Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?

by Ethan Feller

Want to start the week ahead of the pack? Check out Momentum Mondays!

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Zacks Equity Research

HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.

Zacks Equity Research

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

IRadimed (IRMD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 16.13% and 2.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

2 Medical Stocks to Consider Buying in June

by Shaun Pruitt

With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.

Zacks Equity Research

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Centene (CNC) Divests Apixio to Boost Its Core Business

by Zacks Equity Research

Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.

Zacks Equity Research

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.

Zacks Equity Research

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

IRadimed (IRMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 11.11% and 4.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Select Medical (SEM) Buys Richmond Post-Acute Care Facility

by Zacks Equity Research

Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.

Zacks Equity Research

Zacks.com featured highlights include MercadoLibre, iRadimed, Northeast Community Bancorp and AAON

by Zacks Equity Research

MercadoLibre, iRadimed, Northeast Community Bancorp and AAON are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

4 Best Profitable Stocks to Buy Banking on Net Income Ratio

by Tirthankar Chakraborty

MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.

Zacks Equity Research

IRadimed (IRMD) Q4 Earnings Top Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of 3.23% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hologic, Inc. (HOLX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

3 Reasons Growth Investors Will Love iRadimed (IRMD)

by Zacks Equity Research

iRadimed (IRMD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023

by Zacks Equity Research

Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.

Zacks Equity Research

Here is Why Growth Investors Should Buy iRadimed (IRMD) Now

by Zacks Equity Research

iRadimed (IRMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

The Zacks Analyst Blog Highlights ShockWave Medical, iRadimed and Tactile Systems Technology

by Zacks Equity Research

ShockWave Medical, iRadimed and Tactile Systems Technology are part of the Zacks top Analyst Blog.